FGFR2 and neoplasm: If a genetic alteration, such as ERBB2/Her2/neu or FGFR2 amplification, is homogeneously distributed uniformly across the tumor and its different clones, a single tumor-cell-bearing biopsy would be sufficient to reliably document this genetic alteration.